HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa, thereby inhibiting thrombus formation and propagation.
| Metabolism | Heparin is partially metabolized by desulfation and depolymerization via reticuloendothelial system (RES) and is also cleared by the kidneys. Exact enzymatic pathways are not fully characterized; hepatic metabolism is minimal. |
| Excretion | Primarily renal (40-60% as unchanged drug); minor biliary/fecal (<10%). |
| Half-life | 30-150 minutes (dose-dependent, nonlinear); at therapeutic doses ~60-90 minutes; prolonged in hepatic/renal impairment. |
| Protein binding | 90-95% (primarily antithrombin III, albumin, fibrinogen). |
| Volume of Distribution | 0.04-0.07 L/kg (confined to plasma). |
| Bioavailability | SC: 20-30% (dose-dependent). |
| Onset of Action | IV: immediate; SC: 20-30 minutes. |
| Duration of Action | IV: 2-4 hours; SC: 8-12 hours (dose-dependent). |
| Molecular Weight | 12000-15000 Da (average 15000 Da) |
Intravenous: Initial bolus 80 units/kg, then continuous infusion 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for GFR; monitor anti-Xa levels as heparin is partially renally cleared; accumulation risk in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No specific Child-Pugh based adjustments; increased bleeding risk in severe hepatic impairment; monitor aPTT closely. |
| Pediatric use | Intravenous: Bolus 75-100 units/kg, infusion 20-25 units/kg/hour; subcutaneous: 250 units/kg every 12 hours. |
| Geriatric use | Reduce initial bolus and infusion rates (e.g., bolus 50 units/kg, infusion 15 units/kg/hour) due to altered pharmacokinetics and increased bleeding risk; monitor aPTT closely. |
| 1st trimester | Heparin does not cross the placenta; no known teratogenic effects in animal studies or human case series. Use if indicated for thromboembolism. |
| 2nd trimester | No evidence of fetal harm; continues to be safe as it does not cross placenta. Monitor for maternal bleeding and thrombocytopenia. |
| 3rd trimester | Safe; no placental transfer. Risk of maternal hemorrhage at delivery; consider discontinuation or reversal prior to delivery. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Does not cross placenta due to high molecular weight and negative charge. No detectable levels in fetal circulation. |
| Breastfeeding | Heparin is not excreted into breast milk due to its high molecular weight and polarity, making it safe for use during breastfeeding. No adverse effects reported in nursing infants. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Heparin does not cross the placenta due to high molecular weight and negative charge. Risk of teratogenicity is minimal across all trimesters. Use is considered safe during pregnancy, but caution is advised for bleeding risks at delivery. |
| Fetal Monitoring | Monitor platelet count for heparin-induced thrombocytopenia (HIT). Assess for signs of bleeding (e.g., hematuria, bruising). In pregnant women, monitor anti-Xa levels for dose titration (target 0.5-1.0 IU/mL for therapeutic dosing). Fetal monitoring via ultrasound if bleeding complications arise. |
| Fertility Effects | No known adverse effects on fertility from heparin use. It does not interfere with ovulation, implantation, or early embryonic development. |
■ FDA Black Box Warning
Heparin is not intended for intramuscular use. Epidural or spinal hematomas may occur in patients anticoagulated with heparin who receive neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants), traumatic or repeated epidural/spinal puncture, or a history of spinal deformity or spinal surgery. Monitor patients for signs and symptoms of neurological impairment.
| Common Effects | fluid replacement |
| Serious Effects |
History of heparin-induced thrombocytopenia (HIT)Active major bleeding or bleeding diathesis (e.g., hemophilia, thrombocytopenia)Severe uncontrolled hypertensionRecent major surgery, spinal puncture, or organ biopsyHypersensitivity to heparin or pork productsEpidural or spinal anesthesia (risk of spinal hematoma)
| Precautions | Hemorrhage: Risk of major bleeding, including intracranial and retroperitoneal bleeding; monitor coagulation tests (aPTT) and adjust dose accordingly, Heparin-induced thrombocytopenia (HIT): Immune-mediated; can cause thrombosis (HITT); monitor platelet counts regularly, Hypersensitivity reactions: Including urticaria, angioedema, anaphylaxis (especially in patients with history of heparin allergy), Renal impairment: Reduced clearance may require dose adjustment, Elderly: Higher risk of bleeding; use with caution, Neuraxial anesthesia: Risk of spinal/epidural hematoma; monitor neurological status, Heparin resistance: May occur in patients with antithrombin III deficiency or elevated heparin clearance, Hyperkalemia: Heparin can suppress aldosterone synthesis, leading to hyperkalemia; monitor potassium in prolonged use |
| Food/Dietary | No specific food interactions with heparin. However, avoid excessive intake of vitamin K-rich foods (e.g., leafy greens, broccoli, brussels sprouts) if also on warfarin, but heparin alone has no dietary restrictions. Maintain a consistent diet if transitioning to oral anticoagulants. |
| Clinical Pearls | For heparin 10,000 units in 0.9% sodium chloride (typically a solution for IV infusion), confirm patency of IV line before administration to prevent extravasation, which can cause tissue necrosis. Monitor activated partial thromboplastin time (aPTT) 6 hours after initiation or dose change; therapeutic range is 1.5-2.5 times control. Use with caution in patients with renal impairment as clearance may be reduced. Heparin can cause heparin-induced thrombocytopenia (HIT); check platelet counts every 2-3 days. Protamine sulfate (1 mg per 100 units heparin) reverses effects. Do not administer intramuscularly due to risk of hematoma. |
| Patient Advice | Report any signs of bleeding: unusual bruising, black or bloody stools, dark urine, coughing up blood, or bleeding from gums/nose. · Avoid aspirin, NSAIDs (like ibuprofen), and other blood thinners unless prescribed by your doctor. · Use a soft toothbrush and electric razor to minimize bleeding risk. · Do not take any new medications or supplements without consulting your healthcare provider. · Seek immediate medical attention if you experience severe headache, abdominal pain, joint pain, or difficulty breathing. · Inform all healthcare providers (including dentists) that you are taking heparin. |
Loading safety data…